NCT06570447View on ClinicalTrials.gov

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Diffuse Large B-Cell Lymphoma-RecurrentDiffuse Large B-Cell Lymphoma-Refractory
Interventions
DRUG

Glofitamab

For Glofitamab Injection solution, after Obinutuzumab pretreatment on Day 1 of Cycle 1, patients followed a step-dose escalation regimen.

DRUG

Chidamide

Chidamide: 30 mg/d orally twice a week for 21 days as a treatment cycle.

Trial Locations (1)

300060

RECRUITING

Tianjin Medical University Cancer Insititute & Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER